GRN300–001: Phase 1/1B evaluation of the safety, pharmacokinetics, and efficacy of GRN-300, a salt-inducible kinase inhibitor, alone and in combination with paclitaxel, in recurrent ovarian, primary peritoneal, and fallopian tube cancers.

Authors

Siqing Fu

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Siqing Fu , Amir A. Jazaeri , Zhen Lu , Markus Peter , Stephan Wade Morris , Robert C. Bast Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.

First Author: Christos Kyriakopoulos

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

NOVA-II: Part 2 study to evaluate the safety and efficacy of OQL011 on VEGF inhibitor-associated hand-foot skin reaction in patients with cancer.

First Author: Anisha B Patel

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.

First Author: Xiao-Li Wei

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.

First Author: Erica Michelle Stringer-Reasor